Pursuant to section 23(4A) of the Medicines Act 1981, the Minister of Health hereby renews the provisional consent to the sale, supply or use in New Zealand of the medicines set out in the Schedule hereto:
Schedule
Product: | Thalomid |
Active Ingredient: | Thalidomide 50mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Celgene Limited |
Manufacturers: | Penn Pharmaceutical Services Limited, Tredegar, United Kingdom Celgene International Sarl, Boudry, Switzerland |
|
|
Note: This renewed consent is valid for two years from 25 November 2020. | |
Product: | Thalomid |
Active Ingredient: | Thalidomide 100mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Celgene Limited |
Manufacturers: | Penn Pharmaceutical Services Limited, Tredegar, United Kingdom Celgene International Sarl, Boudry, Switzerland |
|
|
Note: This renewed consent is valid for two years from 25 November 2020. | |
Product: | Thalomid |
Active Ingredient: | Thalidomide 150mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Celgene Limited |
Manufacturers: | Penn Pharmaceutical Services Limited, Tredegar, United Kingdom Celgene International Sarl, Boudry, Switzerland |
|
|
Note: This renewed consent is valid for two years from 25 November 2020. | |
Product: | Thalomid |
Active Ingredient: | Thalidomide 200mg |
Dosage Form: | Capsule |
New Zealand Sponsor: | Celgene Limited |
Manufacturers: | Penn Pharmaceutical Services Limited, Tredegar, United Kingdom Celgene International Sarl, Boudry, Switzerland |
|
|
Note: This renewed consent is valid for two years from 25 November 2020. |
Dated this 13th day of November 2020.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).